SCHEMBL22101385

SCHEMBL22101385

O=C(OC1CCOC1)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 5/20 0.54
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
HTR3E A5X5Y0 1/20 0.51
HTR3B O95264 1/20 0.51
HTR3A P46098 1/20 0.51
HTR3D Q70Z44 1/20 0.51
HTR3C Q8WXA8 1/20 0.51
APOBEC3A P31941 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
GAA P10253 1/20 0.49
SCN1A P35498 1/20 0.46
SCN2A Q99250 1/20 0.46
SCN3A Q9NY46 1/20 0.46
CARM1 Q86X55 1/20 0.45
PRMT6 Q96LA8 1/20 0.45
CTSL P07711 1/20 0.44
TSHR P16473 1/20 0.43
BCHE P06276 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14461205 1.00 CHRNA7 (0.54) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL21886707 1.00 CHRNA7 (0.54) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL31376136 0.94 CHRNA7 (0.49) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL12614061 0.90 CHRNA7 (0.51) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL13369465 0.90 CHRNA7 (0.51) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL5185766 0.90 KMT2A (0.59) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL28339381 0.86 CHRNA7 (0.56) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL18670620 0.84 SCN1A (0.57) MEN1KMT2AGAASCN1ASCN2A
SCHEMBL11637921 0.83 CHRNA7 (0.53) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL4453290 0.80 MEN1 (0.69) CHRNA7MEN1KMT2AHTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4499106-A2 NUCLEOSIDE LINE-1 INHIBITORS Transposon Therapeutics, Inc. (US) 2025-02-05 EP disclosed
CN-119278043-A Nucleoside LINE-1 inhibitors 转位治疗股份有限公司 2025-01-07 CN disclosed
EP-4404942-A2 COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF Wave Life Sciences Ltd. (SG) 2024-07-31 EP disclosed
WO-2023178133-A9 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS, INC. (US) 2023-10-26 WO disclosed
WO-2023192491-A2 NUCLEOSIDE LINE-1 INHIBITORS TRANSPOSON THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
WO-2023065683-A1 NOVEL DEUTERATED PURINE NUCLEOSIDE COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION THEREOF, AND APPLICATION THEREOF 广州谷森制药有限公司 2023-04-27 WO disclosed
WO-2023049477-A2 COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-03-30 WO disclosed
EP-3666772-A1 DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2020-06-17 EP disclosed
CN-106166160-A For treating the compositions of HCV 吉利德制药有限责任公司 2016-11-30 CN disclosed
CN-104244945-B METHODS FOR TREATING HCV 吉利德制药有限责任公司 2016-08-31 CN disclosed
CN-105705150-A Mutual prodrugs comprising short chain fatty acids and zebularine or 1' -cyano-cytarabine for cancer treatment 康佳诺医疗科技发展有限公司 2016-06-22 CN disclosed
CN-103087132-B Synthesis of beta-nucleosides PHARMAESSENTIA CORP. (CN) 2016-05-11 CN disclosed